 |
|
|
|
 |
|
|
| Article 1 to 2 out of 2 concerning Calando Pharmaceuticals, Inc.
|
-
Calando Pharmaceuticals, UCLA Medical Center, City of Hope plan to conduct first cancer clinincal trial for RNAi therapeutics
(05/15/2007)
First Human Trials Using Targeted, Formulated siRNA to use NA interference Against Cancer
Calando Pharmaceuticals, together with City of Hope (COH) and the UCLA Jonsson Cancer Center (UCLA), announced that Calando, UCLA and COH are planning a broad-based Phase I clinical trial to begin later this year for Calando's lead drug candidate, ...
-
Alnylam Grants Calando a License to Develop and Commercialize an RNAi Therapeutic Product
(08/23/2006)
Target-Specific License for RNAi Intellectual Property Granted under Alnylam's InterfeRx(TM) Program
Alnylam Pharmaceuticals, Inc. has granted Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation, an InterfeRx(TM) license to discover, develop, and commercialize an RNAi therapeutic utilizing a synthetic siRNA, ...
|
|
|
|
|
Top